Investment
Features
FeesSafety
Academy
More
Pluang+

Himax Technologies beats Q2 revenue and profit forecasts, driven by automotive sales growth.

Analyst Insights
19 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Himax Technologies exceeded its Q2 2026 revenue, margin, and earnings guidance, with automotive silicon now making up over half of its sales. This shift towards automotive products is boosting the company's gross margin to 33.1%, signaling stronger and more sustainable earnings power. The company’s valuation remains attractive with potential growth opportunities in smart glasses, co-packaged optics, and OLED notebook projects. Key risks include supply constraints from mature node foundries and concerns over dividend sustainability if operating cash flow does not improve.

More News

Bitcoin nears key short-term holder cost basis, hinting at potential bullish trend.

Bitcoin nears key short-term holder cost basis, hinting at potential bullish trend.

Bitcoin has recently moved above its 50-day moving average and the short-term holder (STH) realized price, around $67,000. This level represents the average cost basis of coins held for less than 155 days. Historically, when Bitcoin trades above this...

Technical Signals
Bullish
4 hours ago
XRP on-chain trading peaks during London-New York overlap, capturing 23.5% of weekday volume in July 2026.

XRP on-chain trading peaks during London-New York overlap, capturing 23.5% of weekday volume in July 2026.

XRP's on-chain trading volume has increasingly concentrated during a three-hour window overlapping London and New York business hours, capturing 23.5% of weekday volume in July 2026, up from 14.3% a year earlier. This shift suggests growing instituti...

Protocol Fundamentals
Bullish
4 hours ago
Sionna Therapeutics shares plunge 92% after failed cystic fibrosis drug trial triggers shareholder lawsuit

Sionna Therapeutics shares plunge 92% after failed cystic fibrosis drug trial triggers shareholder lawsuit

Sionna Therapeutics' stock dropped 92% after its Phase 2a trial for cystic fibrosis drug SION-719 failed to meet key endpoints, notably reducing sweat chloride levels. This disappointing result has led shareholder rights firm Robbins LLP to investiga...

Market News
Bearish
4 hours ago
Suja Life stock plunges over 70% after weak sales and profit margins post-IPO.

Suja Life stock plunges over 70% after weak sales and profit margins post-IPO.

Suja Life, a producer of organic juices, saw its stock drop more than 70% below its IPO price after reporting a 21% sales decline and a 7.5% drop in gross profit margins in Q2 2026. The company cut its full-year revenue and growth forecasts, citing s...

Market News
Bearish
4 hours ago
Teradyne upgraded to Buy on strong AI-driven growth and attractive dip buying opportunity near $320s.

Teradyne upgraded to Buy on strong AI-driven growth and attractive dip buying opportunity near $320s.

Teradyne (TER) has been upgraded from Hold to Buy due to robust multi-year growth driven by increasing demand for chip testing amid expanding data centers and chip complexity. The company's premium price-to-earnings ratio of 48.74x is supported by st...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App